NDNF inhibits the migration and invasion of human renal cancer cells through epithelial‑mesenchymal transition

Xia,Lingling; Li,Shi; Liu,Yang; Huang,Yuqian; Ni,Beibei; Wan,Lili; Mei,Hongbing; Li,Xianxin; Cai,Zhiming; Li,Zesong

doi:10.3892/ol.2019.9937

NDNF inhibits the migration and invasion of human renal cancer cells through epithelial‑mesenchymal transition

Authors:
- Lingling Xia
- Shi Li
- Yang Liu
- Yuqian Huang
- Beibei Ni
- Lili Wan
- Hongbing Mei
- Xianxin Li
- Zhiming Cai
- Zesong Li
View Affiliations

Affiliations: Guangdong Key Laboratory of Systems Biology and Synthetic Biology for Urogenital Tumors, Shenzhen Second People's Hospital, First Affiliated Hospital of Shenzhen University, Shenzhen, Guangdong 518000, P.R. China, Department of Urology, Peking University Shenzhen Hospital, Shenzhen, Guangdong 518036, P.R. China
Published online on: January 15, 2019 https://doi.org/10.3892/ol.2019.9937
Pages: 2969-2975

Metrics: Total Views: 0 (Spandidos Publications: | PMC Statistics: )

Metrics: Total PDF Downloads: 0 (Spandidos Publications: | PMC Statistics: )

Cited By (CrossRef): 0 citations Loading Articles...

Abstract

Neuron‑derived neurotrophic factor (NDNF) is a glycosylated, disulfide‑bonded secretory protein that contains a fibronectin type III domain. NDNF has been identified as a neurotrophic factor; however, its role in carcinogenesis has not yet been identified. To investigate the expression and role of NDNF in carcinogenesis, the expression of NDNF in human Renal cell carcinoma (RCC) cell lines and tissues was detected by reverse transcription‑quantitative polymerase chain reaction (RT‑qPCR) and western blot analysis. Cell proliferation was investigated using CCK‑8 and colony formation assays, and the cell invasion and immigration capacity was evaluated using the transwell assay. The results demonstrated that NDNF expression was downregulated in RCC cell lines and RCC tissues. Restoring NDNF expression significantly inhibited the proliferation, migration and invasion of RCC cells. The study also demonstrated that the inhibitory effect of NDNF on invasive ability was mediated by suppressing the epithelial‑mesenchymal transition (EMT) in RCC cells. NDNF may therefore be considered an important regulator of EMT in RCC progression and may represent a novel promising target for antimetastatic therapy.

View Figures

View References

1	Siegel RL, Miller KD and Jemal A: Cancer statistics, 2016. CA Cancer J Clin. 66:7–30. 2016. View Article : Google Scholar : PubMed/NCBI
2	Cohen HT and McGovern FJ: Renal-cell carcinoma. N Engl J Med. 353:2477–2490. 2005. View Article : Google Scholar : PubMed/NCBI
3	Das M: Cabozantinib improves clinical outcomes in renal cancer. Lancet Oncol. 18:e22017. View Article : Google Scholar : PubMed/NCBI
4	Liu S, Tian Z, Zhang L, Hou S, Hu S, Wu J, Jing Y, Sun H, Yu F, Zhao L, et al: Combined cell surface carbonic anhydrase 9 and CD147 antigens enable high-efficiency capture of circulating tumor cells in clear cell renal cell carcinoma patients. Oncotarget. 7:59877–59891. 2016.PubMed/NCBI
5	Xu G, Lu X, Huang T and Fan J: ARHGAP24 inhibits cell cycle progression, induces apoptosis and suppresses invasion in renal cell carcinoma. Oncotarget. 7:51829–51839. 2016.PubMed/NCBI
6	El-Mokadem I, Kidd T, Pratt N, Fleming S and Nabi G: Tumour suppressor gene (CDKNA2) status on chromosome 9p in resected renal tissue improves prognosis of localised kidney cancer. Oncotarget. 7:73045–73054. 2016. View Article : Google Scholar : PubMed/NCBI
7	Tang H, Chen Y, Liu X, Wang S, Lv Y, Wu D, Wang Q, Luo M and Deng H: Downregulation of HSP60 disrupts mitochondrial proteostasis to promote tumorigenesis and progression in clear cell renal cell carcinoma. Oncotarget. 7:38822–38834. 2016. View Article : Google Scholar : PubMed/NCBI
8	Kuang XL, Zhao XM, Xu HF, Shi YY, Deng JB and Sun GT: Spatio-temporal expression of a novel neuron-derived neurotrophic factor (NDNF) in mouse brains during development. BMC Neurosci. 11:1372010. View Article : Google Scholar : PubMed/NCBI
9	Ohashi K, Enomoto T, Joki Y, Shibata R, Ogura Y, Kataoka Y, Shimizu Y, Kambara T, Uemura Y, Yuasa D, et al: Neuron-derived neurotrophic factor functions as a novel modulator that enhances endothelial cell function and revascularization processes. J Biol Chem. 289:14132–14144. 2014. View Article : Google Scholar : PubMed/NCBI
10	Joki Y, Ohashi K, Yuasa D, Shibata R, Kataoka Y, Kambara T, Uemura Y, Matsuo K, Hayakawa S, Hiramatsu-Ito M, et al: Neuron-derived neurotrophic factor ameliorates adverse cardiac remodeling after experimental myocardial infarction. Circ Heart Fail. 8:342–351. 2015. View Article : Google Scholar : PubMed/NCBI
11	Dongre A and Weinberg RA: New insights into the mechanisms of epithelial-mesenchymal transition and implications for cancer. Nat Rev Mol Cell Biol. 20–Nov;2018.(Epub ahead of print).
12	Xie J, Zhu C, Wu J, Li C, Luo L, Xia L, Li X, Gui Y, Cai Z and Li Z: Down-regulation of C12orf59 is associated with a poor prognosis and VHL mutations in renal cell carcinoma. Oncotarget. 7:6824–6834. 2016.PubMed/NCBI
13	Luo L, Wu J, Xie J, Xia L, Qian X, Cai Z and Li Z: Downregulated ECRG4 is associated with poor prognosis in renal cell cancer and is regulated by promoter DNA methylation. Tumour Biol. 37:1121–1129. 2016. View Article : Google Scholar : PubMed/NCBI
14	Livak KJ and Schmittgen TD: Analysis of relative gene expression data using real-time quantitative PCR and the 2(-Delta Delta C(T)) method. Methods. 25:402–408. 2001. View Article : Google Scholar : PubMed/NCBI
15	Rhodes DR, Kalyana-Sundaram S, Mahavisno V, Varambally R, Yu J, Briggs BB, Barrette TR, Anstet MJ, Kincead-Beal C, Kulkarni P, et al: Oncomine 3.0: Genes, pathways, and networks in a collection of 18,000 cancer gene expression profiles. Neoplasia. 9:166–180. 2007. View Article : Google Scholar : PubMed/NCBI
16	Gumz ML, Zou H, Kreinest PA, Childs AC, Belmonte LS, LeGrand SN, Wu KJ, Luxon BA, Sinha M, Parker AS, et al: Secreted frizzled-related protein 1 loss contributes to tumor phenotype of clear cell renal cell carcinoma. Clin Cancer Res. 13:4740–4749. 2007. View Article : Google Scholar : PubMed/NCBI
17	Lenburg ME, Liou LS, Gerry NP, Frampton GM, Cohen HT and Christman MF: Previously unidentified changes in renal cell carcinoma gene expression identified by parametric analysis of microarray data. BMC Cancer. 3:312003. View Article : Google Scholar : PubMed/NCBI
18	Yusenko MV, Kuiper RP, Boethe T, Ljungberg B, van Kessel AG and Kovacs G: High-resolution DNA copy number and gene expression analyses distinguish chromophobe renal cell carcinomas and renal oncocytomas. BMC Cancer. 9:1522009. View Article : Google Scholar : PubMed/NCBI
19	Zhou L, Chen J, Li Z, Li X, Hu X, Huang Y, Zhao X, Liang C, Wang Y, Sun L, et al: Integrated profiling of microRNAs and mRNAs: microRNAs located on Xq27.3 associate with clear cell renal cell carcinoma. PLoS One. 5:e152242010. View Article : Google Scholar : PubMed/NCBI
20	Pickard A and McCance DJ: IGF-binding protein 2-oncogene or tumor suppressor? Front Endocrinol (Lausanne). 6(25)2015.PubMed/NCBI
21	Echizen K, Nakada M, Hayashi T, Sabit H, Furuta T, Nakai M, Koyama-Nasu R, Nishimura Y, Taniue K, Morishita Y, et al: PCDH10 is required for the tumorigenicity of glioblastoma cells. Biochem Biophys Res Commun. 444:13–18. 2014. View Article : Google Scholar : PubMed/NCBI
22	Li Z, Chim JC, Yang M, Ye J, Wong BC and Qiao L: Role of PCDH10 and its hypermethylation in human gastric cancer. Biochim Biophys Acta. 1823:298–305. 2012. View Article : Google Scholar : PubMed/NCBI
23	Musgrove EA, Caldon CE, Barraclough J, Stone A and Sutherland RL: Cyclin D as a therapeutic target in cancer. Nat Rev Cancer. 11:558–572. 2011. View Article : Google Scholar : PubMed/NCBI
24	Galichon P, Finianos S and Hertig A: EMT-MET in renal disease: Should we curb our enthusiasm? Cancer Lett. 341:24–29. 2013. View Article : Google Scholar : PubMed/NCBI
25	Piva F, Giulietti M, Santoni M, Occhipinti G, Scarpelli M, Lopez-Beltran A, Cheng L, Principato G and Montironi R: Epithelial to mesenchymal transition in renal cell carcinoma: Implications for cancer therapy. Mol Diagn Ther. 20:111–117. 2016. View Article : Google Scholar : PubMed/NCBI
26	Han WQ, Zhu Q, Hu J, Li PL, Zhang F and Li N: Hypoxia-inducible factor prolyl-hydroxylase-2 mediates transforming growth factor beta 1-induced epithelial-mesenchymal transition in renal tubular cells. Biochim Biophys Acta. 1833:1454–1462. 2013. View Article : Google Scholar : PubMed/NCBI
27	McGuire JK, Li Q and Parks WC: Matrilysin (matrix metalloproteinase-7) mediates E-cadherin ectodomain shedding in injured lung epithelium. Am J Pathol. 162:1831–1843. 2003. View Article : Google Scholar : PubMed/NCBI
28	Tan RJ, Zhou D, Zhou L and Liu Y: Wnt/β-catenin signaling and kidney fibrosis. Kidney Int Suppl (2011). 4:84–90. 2014. View Article : Google Scholar : PubMed/NCBI